IDF releases position paper on bariatric surgery

The International Diabetes Federation has released its Position Statement on Bariatric Surgery. The Paper calls for bariatric surgery to be considered earlier in the treatment of eligible patients, to help stem the serious complications that can result from diabetes. The position paper was presented to leading experts at the 2nd World Congress on Interventional Therapies for Type 2 Diabetes in New York on 28 March.

Sir George Alberti,
Co-Chair of the IDF Task Force
on Epidemiology and Prevention
Paul Zimmett,
Co-Chair of the IDF Task Force
on Epidemiology and Prevention
Paul Zimmet, Francesco Rubino,
Herbert Pardes, John Dixon and
Sir George Alberti

The statement was written by experts in diabetes and bariatric surgery and contains a series of recommendations on the use of weight loss surgery as a cost effective treatment option for severely obese people with type 2 diabetes.

The combination of obesity and type 2 diabetes is looming as the biggest epidemic and public health issue in human history. Type 2 diabetes is one of the fastest growing diseases today with close to 300 million people affected worldwide and 450 million people forecast to have diabetes by 2030.

The statement highlights that there is increasing evidence that the health of obese people with type 2 diabetes, including their glucose control and other obesity related comorbidities (conditions), can benefit substantially from bariatric surgery under certain circumstances.

The IDF Taskforce on Epidemiology and Prevention convened the expert group with specific goals to:

  • Develop practical recommendations for clinicians on patient selection and management
  • Identify barriers to surgical access
  • Suggest health policies that ensure equitable access to surgery
  • Identify priorities for research


Permission to circulate any IDF material must be obtained from the IDF Executive Office in Brussels, Belgium. Requests will be reviewed on the basis of current IDF policy designed to support IDF’s mission to provide treatment, cure and prevention for diabetes in the most ethical way possible. Attempts to directly circulate IDF material in a way which can be construed as being for commercial profit or benefit and in a context which does not fulfil the IDF mission statement would be in direct violation of IDF policy. All requests should be submitted to [email protected].